These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33080906)

  • 1. Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients.
    Curcio A; Romano A; Cuozzo S; Nicola AD; Grassi O; Schiaroli D; Nocera GF; Pironti M
    Medicina (Kaunas); 2020 Oct; 56(10):. PubMed ID: 33080906
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
    Aller R; Izaola O; Gómez S; Tafur C; González G; Berroa E; Mora N; González JM; de Luis DA
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3118-24. PubMed ID: 26367736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.
    Cicero AFG; Colletti A; Bellentani S
    Nutrients; 2018 Aug; 10(9):. PubMed ID: 30142943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Farsi F; Mohammadshahi M; Alavinejad P; Rezazadeh A; Zarei M; Engali KA
    J Am Coll Nutr; 2016; 35(4):346-53. PubMed ID: 26156412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial.
    Anushiravani A; Haddadi N; Pourfarmanbar M; Mohammadkarimi V
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):613-617. PubMed ID: 30920975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease.
    Aller R; Laserna C; Rojo MÁ; Mora N; García Sánchez C; Pina M; Sigüenza R; Durà M; Primo D; Izaola O; de Luis D
    Rev Esp Enferm Dig; 2018 Oct; 110(10):634-640. PubMed ID: 30032630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
    Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress.
    Farhangi MA; Alipour B; Jafarvand E; Khoshbaten M
    Arch Med Res; 2014 Oct; 45(7):589-95. PubMed ID: 25450583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Yang K; Chen J; Zhang T; Yuan X; Ge A; Wang S; Xu H; Zeng L; Ge J
    Front Immunol; 2022; 13():949746. PubMed ID: 36159792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between 25-hydroxyvitamin D concentration and liver enzymes in overweight or obese adults: Cross-sectional and interventional outcomes.
    Naderpoor N; Mousa A; de Courten M; Scragg R; de Courten B
    J Steroid Biochem Mol Biol; 2018 Mar; 177():193-199. PubMed ID: 28899715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats.
    Mengesha T; Gnanasekaran N; Mehare T
    BMC Complement Med Ther; 2021 Mar; 21(1):104. PubMed ID: 33785007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antioxidant cosupplementation therapy with vitamin C, vitamin E, and coenzyme Q10 in patients with oligoasthenozoospermia.
    Kobori Y; Ota S; Sato R; Yagi H; Soh S; Arai G; Okada H
    Arch Ital Urol Androl; 2014 Mar; 86(1):1-4. PubMed ID: 24704922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD.
    Liang J; Liu Y; Liu J; Li Z; Fan Q; Jiang Z; Yan F; Wang Z; Huang P; Feng N
    J Nanobiotechnology; 2018 Sep; 16(1):64. PubMed ID: 30176941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice.
    Sahin E; Bagci R; Bektur Aykanat NE; Kacar S; Sahinturk V
    J Food Biochem; 2020 Jun; 44(6):e13194. PubMed ID: 32189355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study.
    Hajiaghamohammadi AA; Ziaee A; Oveisi S; Masroor H
    Hepat Mon; 2012 Aug; 12(8):e6099. PubMed ID: 23087748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
    Hofmann WP; Buggisch P; Schubert L; Dikopoulos N; Schwenzer J; Muche M; Felten G; Heyne R; Ingiliz P; Schmidt A; Stein K; Wedemeyer H; Berg T; Wiegand J; Lammert F; Zeuzem S; Schattenberg JM
    JHEP Rep; 2020 Dec; 2(6):100168. PubMed ID: 32964201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amelioration of lead toxicity on rat liver with Vitamin C and silymarin supplements.
    Shalan MG; Mostafa MS; Hassouna MM; El-Nabi SE; El-Refaie A
    Toxicology; 2005 Jan; 206(1):1-15. PubMed ID: 15590105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight reduction improves markers of hepatic function and insulin resistance in type-2 diabetic patients with non-alcoholic fatty liver.
    Al-Jiffri O; Al-Sharif FM; Abd El-Kader SM; Ashmawy EM
    Afr Health Sci; 2013 Sep; 13(3):667-72. PubMed ID: 24250305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
    Alami F; Alizadeh M; Shateri K
    Scand J Gastroenterol; 2022 Oct; 57(10):1238-1249. PubMed ID: 35710164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease: relation to juvenile obesity, lipid profile, and hepatic enzymes.
    Altalebi RR; Al-Hussaniy HA; Al-Tameemi ZS; Al-Zobaidy MA; Albu-Rghaif AH; Alkuraishy HM; Hedeab GM; Azam F; Al-Samydai AM; Naji MA
    J Med Life; 2023 Jan; 16(1):42-47. PubMed ID: 36873135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.